Wednesday, February 1, 2023
Pliant Therapeutics (NASDAQ: PLRX) Reports Positive Phase 2 Clinical Trial Data of Bexotegrast in Treatment of Idiopathic Pulmonary Fibrosis
Pliant Therapeutics, Inc. (NASDAQ: PLRX) is engaged as a clinical-stage biopharmaceutical company, which is focused on the research and development...
Read more
NeuroSense Therapeutics (NASDAQ: NRSN) Shares Positive Final Results From Alzheimer’s Disease Biomarker Study
NeuroSense Therapeutics, Ltd. (NASDAQ: NRSN) is a clinical-stage biotechnology company, which is focused on the research and development of treatments...
Read more
Neovasc (NASDAQ: NVCN) (TSX: NVCN) Enters into Agreement to be Acquired by Shockwave Medical (NASDAQ: SWAV) for $100 Million & CVR
Neovasc, Inc. (NASDAQ: NVCN) (TSX: NVCN) is engaged as a specialty medical device company, which is focused on the development,...
Read more
CinCor Pharma (NASDAQ: CINC) Enters Into Agreement to be Acquired by AstraZeneca (NASDAQ: AZN) for $1.3 Billion
CinCor Pharma, Inc. (NASDAQ: CINC) is a clinical-stage biopharmaceutical company, which is focused on the research and development of treatments...
Read more
Spruce Biosciences (NASDAQ: SPRB) Enters Into Collaboration with Kaken Pharmaceutical to Develop Tildacerfont for CAH in Japan
Spruce Biosciences, Inc. (NASDAQ: SPRB) is engaged as a late-stage biopharmaceutical company, which is focused on the research, development and...
Read more
Geron (NASDAQ: GERN) Reports Positive Results From IMerge Phase 3 Trial of Imetelstat for Lower Risk MDS
Geron Corporation (NASDAQ: GERN) is engaged as a late-stage biopharmaceutical company, which is focused on the research and development of...
Read more
Silo Pharma (NASDAQ: SILO) Reports Positive Results from Dose Optimization Study for SPU-21 and Treatment of Arthritis
Silo Pharma, Inc. (NASDAQ: SILO) operates as a development-stage biopharmaceutical company, which is focused on combining traditional therapies with psychedelics...
Read more
Kala Pharmaceuticals (NASDAQ: KALA) Says FDA Accepted its IND Application for KPI-012 and Treatment of PCED
Kala Pharmaceuticals, Inc. (NASDAQ: KALA) is engaged as a clinical-stage biopharmaceutical company, which is focused on the research, development and...
Read more
Madrigal Pharmaceuticals (NASDAQ: MDGL) Reports Impressive Topline Results from Phase 3 Trial of Resmetirom to Treat NASH and Liver Fibrosis
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) is engaged as a clinical-stage biopharmaceutical company, which is focused on the research and development...
Read more
Kintara Therapeutics (NASDAQ: KTRA) Granted Orphan Drug Status for VAL-083 and the Treatment of Diffuse Intrinsic Pontine Glioma (DIPG)
Kintara Therapeutics, Inc. (NASDAQ: KTRA) is engaged as a biopharmaceutical company, which is focused on the research and development of...
Read more
